Table 1.

Values of disease costs used in a partial budget model to evaluate the economic benefit of using Rumensin Controlled Release Capsule (CRC) to reduce disease incidence and increase milk production and to evaluate the economic benefit of using propylene glycol (PG) to treat cows with ketosis when diagnosed by different cow-side tests. All values listed are in Canadian dollars

	Disease
Cost estimate	DA	MET	MAST	RP	CK	KET
Total loss	905	507	572	403	233	203
Losses excluding milk lossc	833a,b	—	—	—	—	—
Losses excluding milk loss, veterinary fees, and drugs	—	271a	303a	255a	53a,b	—
Losses after excluding the cost of clinical disease risk (DA, MET, CK) attributable to ketosis	—	—	—	—	—	127a
Losses after excluding the cost of clinical disease risk (DA, CK) and culling attributable to ketosis	—	—	—	—	—	152b

DA — displaced abomasum; MET — metritis; MAST — mastitis; RP — retained placenta; CK — clinical ketosis; cases of ketosis identified by clinical signs regardless of serum BHBA concentrations; KET — ketosis; defined as elevated serum BHBA ≥ 1400 μmol/L in either of the first 2 wk following calving and without showing clinical signs.

^aValues used in the partial budget model to estimate the economic value of Rumensin CRC to reduce disease incidence and increase milk production.

^bValues used in the partial budget model to estimate the economic value of PG to treat cows with ketosis.

^cThe cost of milk loss only was excluded from the total cost of a DA because veterinary fees and drug costs are unique to the surgery.